Lynparza and Imfinzi demonstrated strong clinical benefit and more than doubled median duration of response vs. chemotherapy in patients with pMMR advanced or recurrent endometrial cancer
Clinical benefit with Imfinzi was greatest in the mismatch repair deficient subgroup. Results from the DUO-E trial reinforce potential of both Imfinzi and the Lynparza and Imfinzi regimen in endometrial cancer. Latest analysis of the results from the DUO-E Phase III trial showed Imfinzi (durvalumab) plus platinum-based chemotherapy followed by Imfinzi plus Lynparza (olaparib) (Lynparza and Imfinzi arm) demonstrated an improvement in multiple key secondary efficacy endpoints, particularly in patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer compared